Patents by Inventor THOMAS CHARLES PERTEL
THOMAS CHARLES PERTEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240085403Abstract: The instant disclosure relates to methods for preventing, controlling and/or inhibiting the rare events of adventitious viral infection or viral replication/amplification after reactivation of latent viral infection during cell culture in the manufacturing process of cell-based drug products, including CAR T cell drug products. Also provided are in vitro cell culture models for HHV-6 latent infection and methods of making the same.Type: ApplicationFiled: August 16, 2023Publication date: March 14, 2024Inventors: Thomas Charles PERTEL, Ren SONG, Diego A. VARGAS-INCHAUSTEGUI, Garima YAGNIK, Houman DEHGHANI, Wenjing LI, Jose PENA
-
Patent number: 11912776Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: March 15, 2022Date of Patent: February 27, 2024Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Patent number: 11896617Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.Type: GrantFiled: April 24, 2020Date of Patent: February 13, 2024Assignee: ALLOGENE THERAPEUTICS, INC.Inventors: Thomas Charles Pertel, Barbra Johnson Sasu, Mark W. Leonard
-
Publication number: 20240003056Abstract: The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.Type: ApplicationFiled: July 18, 2023Publication date: January 4, 2024Inventors: Thomas Charles PERTEL, Barbra Johnson SASU
-
Publication number: 20230407252Abstract: Provided herein are methods, kits and reagents for analyzing the attributes of cell populations, such as donor cells prior to modification to provide engineered cells, e.g., engineered immune cells, such as CAR T cells. For example, provided herein are methods of determining the amount or percentage of biomarkers and/or secretion profiles of donor cell populations, selecting donor cells with certain biomarkers and/or secretion profiles, and engineering the CAR T cells from the selected donor cells.Type: ApplicationFiled: April 28, 2023Publication date: December 21, 2023Inventors: Meng-Yin LIN, Hayung YOON, Thomas Charles PERTEL, Barbra Johnson SASU
-
Patent number: 11781248Abstract: The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.Type: GrantFiled: June 12, 2020Date of Patent: October 10, 2023Assignee: ALLOGENE THERAPEUTICS, INC.Inventors: Thomas Charles Pertel, Barbra Johnson Sasu
-
Patent number: 11732041Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.Type: GrantFiled: April 17, 2020Date of Patent: August 22, 2023Assignee: ALLOGENE THERAPEUTICS, INC.Inventors: Thomas Charles Pertel, Barbra Johnson Sasu, Tao Sai
-
Publication number: 20220340671Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: ApplicationFiled: March 15, 2022Publication date: October 27, 2022Inventors: Tracy Chia-Chien KUO, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Patent number: 11312782Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: April 15, 2019Date of Patent: April 26, 2022Assignee: Pfizer Inc.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Publication number: 20220033462Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.Type: ApplicationFiled: July 26, 2021Publication date: February 3, 2022Applicants: ALLOGENE THERAPEUTICS, INC., CELLECTISInventors: ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
-
Patent number: 11072644Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.Type: GrantFiled: November 9, 2015Date of Patent: July 27, 2021Assignees: Allogene Therapeutics, Inc., CellectisInventors: Arvind Rajpal, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
-
Publication number: 20210062150Abstract: Provided herein are methods for preparing T cells for T cell therapy comprising contacting a cell population at a predetermined cell density, with a concentration of an anti-CD3/CD28 nanomatrix and culturing the cells thereby producing a T cell population comprising an increased percentage of at least one T cell subtype. In some embodiments, the method increases the percentage of stem memory T cells.Type: ApplicationFiled: September 2, 2020Publication date: March 4, 2021Inventors: Yajin NI, Chupei ZHANG, Mark W. LEONARD, Thomas Charles PERTEL
-
Publication number: 20200392252Abstract: The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.Type: ApplicationFiled: June 12, 2020Publication date: December 17, 2020Inventors: Thomas Charles PERTEL, Barbra Johnson SASU
-
Publication number: 20200384026Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.Type: ApplicationFiled: April 24, 2020Publication date: December 10, 2020Inventors: Thomas Charles PERTEL, Barbra Johnson SASU, Mark W. LEONARD
-
Publication number: 20200339944Abstract: Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).Type: ApplicationFiled: April 24, 2020Publication date: October 29, 2020Inventors: Diego A. VARGAS-INCHAUSTEGUI, Thomas Charles PERTEL, Barbra Johnson SASU
-
Publication number: 20200331998Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.Type: ApplicationFiled: April 17, 2020Publication date: October 22, 2020Inventors: Thomas Charles PERTEL, Barbra Johnson SASU, Tao SAI
-
Publication number: 20190241669Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: ApplicationFiled: April 15, 2019Publication date: August 8, 2019Inventors: Tracy Chia-Chien KUO, Bijan Andre BOLDAJIPOUR, Javier Fernando CHAPARRO RIGGERS, Philippe DUCHATEAU, Roman Ariel GALETTO, Alexandre JUILLERAT, Thomas Charles PERTEL, Arvind RAJPAL, Barbra Johnson SASU, Cesar Adolfo SOMMER, Julien VALTON, Thomas John VAN BLARCOM
-
Patent number: 10294304Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: March 30, 2016Date of Patent: May 21, 2019Assignee: Pfizer Inc.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Publication number: 20180044399Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V orType: ApplicationFiled: November 9, 2015Publication date: February 15, 2018Applicants: Rinat Neuroscience Corp., CellectisInventors: Arvind RAJPAL, Shobha Chowdary POTLURI, Laurent POIROT, Alexandre JUILLERAT, Thomas Charles PERTEL, Donna Marie STONE, Barbra Johnson SASU
-
Publication number: 20160297884Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: ApplicationFiled: March 30, 2016Publication date: October 13, 2016Inventors: TRACY CHIA-CHIEN KUO, BIJAN ANDRE BOLDAJIPOUR, JAVIER FERNANDO CHAPARRO RIGGERS, PHILIPPE DUCHATEAU, ROMAN GALETTO, ALEXANDRE JUILLERAT, THOMAS CHARLES PERTEL, ARVIND RAJPAL, BARBRA JOHNSON SASU, CESAR ADOLFO SOMMER, JULIEN VALTON, THOMAS JOHN VAN BLARCOM
